News Analysis

Most Recent

HOUSTON. Amgen, the largest biotechnology company in the world, is funding research focusing on disorders that destroy parts of the nervous system. These include Alzheimer's disease, Parkinson's disease, multiple sclerosis and stroke. Medicines for disorders resulting from dysfunction of the neuroendocrine system such as obesity and Type 2 diabetes are also under development. In both areas, Amgen licenses product candidates and technologies that complement its internal drug discovery and develop


New companies to commercialise neuroscience discoveries

By | November 3, 2000

Neurogenomics has significant commercial potential by way of gene targets for enhancement of brain function and treatment of brain-based disease.


Senior scientists promise to boycott journals

By | November 2, 2000

Leading scientists will refuse to publish, edit or subscribe to journals that do not make research articles available free of charge.


BSE Inquiry out in the open

By | October 26, 2000

The results of the UK government's BSE Inquiry were published on Thursday 26 October, implicating civil servants and scientists in the health scandal.


Solving protein folding in your lunch break

By | October 25, 2000

While you take time out to eat your lunch, your computer could be busy helping crack one of the biggest challenges of modern biology.


EU directive on clinical trials will cost lives

By | October 23, 2000

The volume of research conducted in Europe will be driven down dramatically and thousands of lives will be lost if a directive developed by the EU becomes law next year, warned leading UK research directors last week.


A leading cancer trial specialist warns that over-complexity of trials could be delaying the process by which successful drugs reach patients. Professor Richard Gray, Director of the Clinical Trials Unit at the University of Birmingham, voiced his concerns at the European Society for Medical Oncology conference. He called for a move towards simpler and more direct planning and organisation of trials.Currently, trials involve a great demand on patients to undergo extra investigations and attend f


The first test

October 11, 2000

Genetic testing for Huntingdon's disease by insurance companies is to be sanctioned by UK ministers this week. Opposition to this decision by members of parliament and consumer groups raised concerns that DNA testing for insurance purposes would create a 'genetic underclass' of people unable to gain cover, or having to pay higher premiums. People would be forced to disclose the results of a DNA test or risk rendering their cover null or void.A spokeswoman for the National Consumer Council warned


Children's clinical drug trials now mandated in US

By | October 10, 2000

A new law in the US requiring new adult drugs to be tested for use in children could result in a three-fold increase in the number of pediatric clinical trials.


Slow synaptic transmission grabs the Nobel for Physiology or Medicine.


Popular Now

  1. Gut Microbes Linked to Neurodegenerative Disease
  2. Infant Microbiome: Vaginal Delivery Versus C-Section
  3. Top 10 Innovations 2016
    Features Top 10 Innovations 2016

    This year’s list of winners celebrates both large leaps and small (but important) steps in life science technology.

  4. Opinion: WHO’s Silence on Cannabis